Who was studied, and how
Three numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
69people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
exenatide
insulin glargine
Probably raised combined glucose- and arginine-stimulated C-peptide secretion2.5×
Reported lower A1C, no range given−0.10
Reported lower body weight, no range given−4.60
randomisedthe abstract, start to end
… C-peptide secretion was 2.46-fold (95% CI 2.09-2.90, P < …
… glargine reduced A1C similarly: -0.8 +/- 0.1 and -0.7 +/- 0.2%, respectively …
… with insulin glargine (difference -4.6 kg, P < 0.0001). beta-Cell …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Combined glucose- and arginine-stimulated C-peptide secretionexenatide vs insulin glargine
RR 2.462.09–2.90
A1Cexenatide vs insulin glargine
−0.10
Body weightexenatide vs insulin glargine
−4.6
GLP-1 receptor agonistsGlycemic controlBody weight & composition
1 / 5